NEW YORK (GenomeWeb) – Caprion Biosciences said today that it has acquired the assets of ImmuneHealth's immune monitoring laboratory for an undisclosed amount.
Caprion said that it will use the laboratory to "expand its immune monitoring offering and strengthen its business partnerships and research collaborations throughout Europe." The acquisition will also allow Caprion to move into new areas including infectious disease and vaccine development.
"This European expansion is a core part of Caprion's strategy to strengthen our competitive positioning and expand our service offering to better support our pharma and biotech clients as part of their global and European clinical trial initiatives," Caprion President and CEO Martin LeBlanc said in a statement. He added that the acquisition also gives the company access to a new network of business partners.
Caprion's business is built around two primary services: its ProteoCarta proteomics platform, and its ImmuneCarta platform for immune system monitoring in drug development.